GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Telo Genomics Corp (OTCPK:TDSGF) » Definitions » Earnings per Share (Diluted)
中文

Telo Genomics (Telo Genomics) Earnings per Share (Diluted) : $-0.04 (TTM As of Dec. 2023)


View and export this data going back to 2016. Start your Free Trial

What is Telo Genomics Earnings per Share (Diluted)?

Telo Genomics's Earnings per Share (Diluted) for the three months ended in Dec. 2023 was $-0.01. Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $-0.04.

Telo Genomics's EPS (Basic) for the three months ended in Dec. 2023 was $-0.01. Its EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2023 was $-0.04.

Telo Genomics's EPS without NRI for the three months ended in Dec. 2023 was $-0.01. Its EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2023 was $-0.04.

During the past 3 years, the average EPS without NRIGrowth Rate was -7.70% per year. During the past 5 years, the average EPS without NRI Growth Rate was 30.80% per year. During the past 10 years, the average EPS without NRI Growth Rate was 15.40% per year.

During the past 12 years, Telo Genomics's highest 3-Year average EPS without NRI Growth Rate was 65.70% per year. The lowest was -114.50% per year. And the median was 11.60% per year.


Telo Genomics Earnings per Share (Diluted) Historical Data

The historical data trend for Telo Genomics's Earnings per Share (Diluted) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Telo Genomics Earnings per Share (Diluted) Chart

Telo Genomics Annual Data
Trend Dec13 Dec14 Dec15 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
Earnings per Share (Diluted)
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.06 -0.03 -0.02 -0.03 -0.04

Telo Genomics Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Earnings per Share (Diluted) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.01 -0.01 -0.02 -0.01 -0.01

Competitive Comparison of Telo Genomics's Earnings per Share (Diluted)

For the Diagnostics & Research subindustry, Telo Genomics's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Telo Genomics's PE Ratio Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Telo Genomics's PE Ratio distribution charts can be found below:

* The bar in red indicates where Telo Genomics's PE Ratio falls into.



Telo Genomics Earnings per Share (Diluted) Calculation

Earnings Per Share (EPS) is the amount of earnings per outstanding share of the company's stock. In calculating earnings per share, the dividends of preferred stocks need to subtracted from the total net income first.

Telo Genomics's Earnings Per Share (Diluted) for the fiscal year that ended in Jun. 2023 is calculated as

Diluted Earnings Per Share (A: Jun. 2023 ) = (Net Income - Preferred Dividends) / Shares Outstanding (Diluted Average)
=(-2.123-0)/60.152
=-0.04

Telo Genomics's Earnings Per Share (Diluted) for the quarter that ended in Dec. 2023 is calculated as

Diluted Earnings Per Share (Q: Dec. 2023 )=(Net Income - Preferred Dividends / Shares Outstanding (Diluted Average)
=(-0.622-0)/71.310
=-0.01

Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.04

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Companies also reported diluted shares in their financial reports. Diluted shares include the shares of convertibles or warrants outstanding.


Telo Genomics  (OTCPK:TDSGF) Earnings per Share (Diluted) Explanation

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


Telo Genomics Earnings per Share (Diluted) Related Terms

Thank you for viewing the detailed overview of Telo Genomics's Earnings per Share (Diluted) provided by GuruFocus.com. Please click on the following links to see related term pages.


Telo Genomics (Telo Genomics) Business Description

Traded in Other Exchanges
Address
101 College Street, Suite 200, MaRS Centre, South Tower, Toronto, ON, CAN, M5G 1L7
Telo Genomics Corp is a personalized medicine company. The company through its wholly-owned subsidiary is engaged in the development and commercialization of diagnostic and prognostic products. The company is developing diagnostic and prognostic products for cancer and neurological disorders.